Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Revenue	$ 10,126			$ 8,923				$ 32,230	$ 27,762
Other revenue	292	$ 57	$ 46	39			$ 103	395	108
Provision for credit losses	1,385	4,095	5,297	223			9,392	10,777	(459)
Loss on impairment of intangibles assets	0			0				5,771	0
Interest expense	1,139			176				3,514	721
Pharmaceutical manufacturing, research and development expense	585			606				1,635	2,834
Change in fair value of acquisition-related contingent consideration	0	4,900		0				(4,900)	0
Depreciation and amortization expense	234			652				1,169	1,937
General and administrative expense	2,993			2,979				8,600	8,516
Other expense, net	292			(238)				3,727	(319)
Income tax expense (benefit)	906			(386)				2,170	959
Net income (loss)	3,468	$ 3,680	$ 468	4,474	$ 3,934	$ 4,635	$ 4,148	7,616	13,043
Segment Reporting, Reconciling Item, Corporate Nonsegment
Segment Reporting Information [Line Items]
Revenue	0			0				0	0
Other revenue	0			0				0	2
Provision for credit losses	0			0				0	0
Loss on impairment of intangibles assets								0
Interest expense	907			0				2,687	0
Pharmaceutical manufacturing, research and development expense	0			0				0	0
Change in fair value of acquisition-related contingent consideration								0
Depreciation and amortization expense	20			22				63	30
General and administrative expense	2,183			2,192				6,164	5,854
Other expense, net	0			0				(408)	0
Income tax expense (benefit)	906			(386)				2,170	959
Net income (loss)	(4,016)			(1,828)				(11,492)	(6,841)
Finance Receivables | Operating Segments
Segment Reporting Information [Line Items]
Revenue	9,498			8,608				30,519	27,146
Other revenue	289			39				392	106
Provision for credit losses	1,385			223				10,777	(459)
Loss on impairment of intangibles assets								0
Interest expense	230			176				820	721
Pharmaceutical manufacturing, research and development expense	0			0				0	0
Change in fair value of acquisition-related contingent consideration								0
Depreciation and amortization expense	0			0				0	0
General and administrative expense	88			213				257	380
Other expense, net	292			(238)				4,135	(319)
Income tax expense (benefit)	0			0				0	0
Net income (loss)	8,376			7,797				23,192	26,291
Pharmaceutical Development and Other | Operating Segments
Segment Reporting Information [Line Items]
Revenue	628			315				1,711	616
Other revenue	3			0				3	0
Provision for credit losses	0			0				0	0
Loss on impairment of intangibles assets								5,771
Interest expense	2			0				7	0
Pharmaceutical manufacturing, research and development expense	585			606				1,635	2,834
Change in fair value of acquisition-related contingent consideration								(4,900)
Depreciation and amortization expense	214			630				1,106	1,907
General and administrative expense	722			574				2,179	2,282
Other expense, net	0			0				0	0
Income tax expense (benefit)	0			0				0	0
Net income (loss)	$ (892)			$ (1,495)				$ (4,084)	$ (6,407)